Could Aspirin Treatment Modify the Assessment of the Uterine Arteries?

O tratamento com aspirina pode modificar a avaliação das artérias uterinas?

Gabriela Marisol Vallejo1 Montserrat Uriel1 Alexandra Porras-Ramírez2 Ximena Carolina Romero1

1 Universidad El Bosque, El Bosque Research Group of Maternal Fetal, Medicine and Gyneceology, Ecodiagnóstico El Bosque SAS, Los Cobos Medical Center, Bogotá, Colombia
2 Research Group Community Medicine and Collective Health, El Bosque University, Los Cobos Medical Center, Bogotá, Colombia

Address for correspondence Ximena Romero Infante, MD, Universidad El Bosque, Av. Carrera 9 # 131a-02. 110121000, Ecodiagnóstico El Bosque S. A. S, Calle 134 # 78 – 83, Bogotá, Colombia (e-mail: romeroximena@unbosque.edu.co).

Rev Bras Ginecol Obstet 2022;44(3):231–237.

Abstract

Objective To analyze whether acetylsalicylic (ASA) intake modifies the mean uterine arteries pulsatility index (UtA-PI) at the 2nd or 3rd trimester in a cohort of pregnant women with abnormal mean UtA-PI at between 11 and 14 weeks of gestation.

Methods This is a retrospective cohort study. Singleton pregnancies with abnormal mean UtA-PI at between 11 and 14 weeks of gestation were studied. The participants were divided into 3 groups: 1) If the participant did not take ASA during pregnancy; 2) If the participant took ASA before 14 weeks of gestation; and 3) If the participant took ASA after 14 weeks of gestation. The mean UtA-PI was evaluated at the 2nd and 3rd trimesters, and it was considered to improve when it decreased below the 95th percentile. The prevalence ratio (PR) and the number needed to treat (NNT) were calculated.

Results A total of 72 participants with a mean UtA-PI > 95th percentile at the 1st trimester of gestation were evaluated. Out of the 18 participants who took ASA, 8 participants started it before 14 weeks of gestation and 10 after. A total of 33.3% of these participants had improved the mean UtA-PI at the 2nd and 3rd trimesters of gestation, although it was not statistically significant (p = 0.154). The prevalence ratio was 0.95 (95% confidence interval [CI]: 0.31–1.89), but between the 1st and 2nd trimesters of gestation, the PR was 0.92 (95%CI: 0.21–0.99) and it was statistically significant.

Conclusion The present work demonstrates a modification of the mean UtA-PI in participants who took ASA compared with those who did not. It is important to check if ASA can modify the normal limits of uterine arteries because this could have an impact on surveillance.

Keywords ► aspirin ► pre-eclampsia ► ultrasonography ► doppler ► uterine artery

DOI https://doi.org/10.1055/s-0042-1742411. © 2022. Federação Brasileira de Ginecologia e Obstetrícia. All rights reserved.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Introduction

Pre-eclampsia (PE) is an obstetric complication associated with remarkable maternal and perinatal morbidity and mortality worldwide. About 18% of maternal deaths are secondary to hypertensive disorders of pregnancy, and in developing countries it can reach up to 35%. The pathophysiology of PE is not yet fully understood, but it is considered that one of the most important factors is placental ischemia, secondary to an inadequate trophoblastic invasion of the maternal spiral arteries with subsequent vasoconstriction, release of antiangiogenic factors, and endothelial damage, which will be reflected in the clinical manifestations of the disease.

The measurement of the mean uterine arteries pulsatility index (UtA-PI) using the Doppler technique is an indirect validated indicator of trophoblastic invasion and placental perfusion and can be altered in the early stages of gestation. Determination of the mean UtA-PI at the 1st trimester of gestation is one of the elements of a diagnostic algorithm that also combines maternal factors, mean arterial pressure (MAP), maternal serum pregnancy-associated plasma protein-A (PAPP-A) and placental growth factor (PlGF). This model detects about 75% of the patients who will suffer preterm PE with a false positive rate of 10%. Additionally, it described that the combined screening early in the 3rd trimester (30 to 34 weeks) predicted almost all cases of preterm PE and half of term PE with a false positive rate of 5%.

Acetylsalicylic is an anti-inflammatory medication that could decrease resistance in the uteroplacental blood flow by inhibiting thromboxane-mediated vasoconstriction and permitting prostacyclin-mediated vasodilation. Recently, The Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Pre-eclampsia Prevention (ASPREE) trial reported that ASA at a dose of 150 mg per day, started between 11 and 14 weeks, reduces the incidence of preterm PE by 62% in patients with a high risk of developing PE, but a meta-analysis aimed at assessing the impact of the start of ASA intake at the 2nd trimester in women with abnormal UtA-PI showed no benefit regarding the reduction of PE, suggesting that its action is lost after week 16. Currently, there are not enough data to explain how the mean UtA-PI behaves as the gestation progresses when women take ASA before 14 weeks and it has not been explored whether ASA could modify the 95th percentile of mean UtA-PI when patients with high risk of PE at the 2nd and 3rd trimesters are followed-up. The present study aimed to analyze whether ASA intake could modify the mean UtA-PI at the 2nd or 3rd trimesters in a cohort of pregnant women with abnormal mean UtA-PI (PI > 95th percentile) at the 1st trimester.

Methods

This was a retrospective cohort study of prospectively collected data from singleton pregnancies attending for a routine ultrasound scan at the 1st, 2nd, and 3rd trimesters performed between 2014 and 2017 in an obstetric ultrasound center attached to El Bosque University. All participants with abnormal Doppler of uterine arteries, considered...
as mean UtA PI > 95th percentile between 11 and 13 + 6 weeks (dated by CRL), were included. The exclusion criteria were 1) patients with losses in the follow-up of UtA Doppler at the 2nd and 3rd trimesters; 2) participants with multiple pregnancy; and 3) maternal age < 14 years old.

The following demographic characteristics were obtained: maternal age, ethnic origin, body mass index (BMI), comorbidities, smoking during pregnancy, primiparous, and personal and family history of preeclampsia. The visits were made between 11 and 13 + 6 weeks, between 18 and 23 + 6 weeks, and between 28 and 31 + 6 weeks.

The measurement of the mean value of the left and right UtA-PI was performed by specialists in maternal fetal medicine certified by the Fetal Medicine Foundation, using color Doppler ultrasound according to a standardized protocol for each of the trimesters and following the international guidelines. For the 1st trimester examination, a midsagittal section of the uterus with a transvaginal transducer was obtained and the cervical canal and internal cervical OS were identified. The transducer was then moved laterally, and color flow mapping was used to identify each paracervical vascular plexus and the right and left UtA adjacent to the cervix at the level of the internal cervical OS. The samples of pulsed Doppler were established at 2 mm to cover the entire vessel with an insonation angle < 30°. When three similar consecutive waveforms were acquired, the PI was measured, and the mean PI of both arteries was calculated and registered (►Fig. 1).

Pregnancies at 18 to 23 + 6 weeks and between 28 and 31 + 6 weeks were examined transabdominally with the probe placed parallel to the iliac crest and color Doppler imaging was used to identify the UtA, which was measurement 1 cm distal from the crossover point of the iliac artery with the UtA. In all cases, with an angle < 30°, the pulsed Doppler gate was placed over the whole width of the vessel with a maximum size of 2 mm. Angle correction was then applied and the signal was updated until three similar consecutive waveforms had been acquired. The PI of the left and right arteries was measured, and the mean PI was calculated and registered (►Fig. 2).

Fig. 1 Uterine arteries pulsatility index measurements. Source: Sotiriadis et al., Plasencia et al., Martin et al., and Gómez et al.

Fig. 2 Mean UtA-PI of each trimester in the groups: non-ASA, ASA before week 14, and ASA after week 14. Source: Sotiriadis et al., Plasencia et al., Martin et al., and Gómez et al.
Since the main prospective study was not an intervention study, the participants attended with their treating doctor, who defined the start of ASA at a dose of 100 mg orally (only dosage form available in Colombia at that time) and the gestational age of its onset. At each follow-up visit, patients were questioned regarding ASA intake and if the answer was affirmative, the gestational age of onset reported by the participant was recorded.

The participants were divided into three groups: 1) if the participant did not take ASA during pregnancy, 2) if the participant had started ASA intake before week 14, and 3) if the participant took ASA after week 14. Although some studies indicate that the optimal time for initiating ASA administration is ≤ 16 weeks, in the present study, it was established a cutoff point at 14 weeks based on the recently published ASPRE study.19

The outcome was defined by the improvement of mean UtA-PI < 95th percentile for the gestational age at the 2nd and/or 3rd trimesters using the ranges of reference informed by Gómez et al.26 In the present study, the effectiveness of ASA was defined by achieving this outcome.

Comparisons of prevalence ratios (PRs)27–30 were analyzed and, to measure the effectiveness of ASA intake, the number needed to treat (NNT) was used. IBM SPSS Statistics for Windows, Version 24 (IBM Corp., Armonk, N.Y., USA) was used for all data analysis.

The study was approved by the local ethics committee of the Universidad El Bosque (resolution number 006–2014) and by the ethics committee of the Kennedy Hospital Services Unit, and the participants signed the informed consent form. In the present study, the Principles of Helsinki and of resolution 8430 from October 4, 1993, were taken into account.31,32

### Results

A total of 78 participants of the main prospective study had the mean UtA-PI > 95th percentile, a total of 6 participants were excluded (5 participants who presented with late abortions and another who did not attend to the follow-up appointment). Among the 72 participants evaluated, it was found that 18 took ASA (25%), only 8 of whom started ASA intake before 14 weeks, and 10 after 14 weeks (broken down as follows: 2 participants started ASA at 16 weeks, 1 at week 18, 1 at week 20, 5 at 22 weeks, and 1 at 28 weeks). – Table 1 compares the social and clinical characteristics of the women studied. – Fig. 2 shows the mean UtA-PI of each trimester in each group. It was found that out of the total of women who used ASA, 33.3% (n = 6) had an improvement of the mean UtA-PI at the 2nd and 3rd trimesters, even though it was not statistically significant (p = 0.154); and from these 6 participants, 33.3% (n = 2) started the intake of ASA before 14 weeks (p = 0.236) (Fig. 3).

The PR that was found for the effectiveness of ASA at the 2nd and/or 3rd trimesters was 0.95 (95% confidence interval [CI]: 0.31–1.89). On the other hand, the PR found for the effectiveness of ASA in the improvement of mean UtA-PI at the 1st trimester compared with the 2nd trimester was 0.92 (95% CI: 0.21–0.99) which was was statistically significant. In the ASA before the 14th week group, 50% of the patients had improved the mean UtA-PI at the 2nd trimester. The NNT was 24, that is mean that, out of every 24 patients, 1 patient improves the mean UtA-PI at the 2nd trimester in the aspirin group. The PR found for the effectiveness of ASA for the improvement the mean UtA-PI when it was abnormal at the 1s and 2nd trimesters and then normal at the 3rd trimester.

**Table 1** Social and clinical characteristics of the group of participants

| Characteristics | No-ASA n = 54 | ASA group before 14 weeks n = 8 | ASA group after 14 weeks n = 10 |
|-----------------|--------------|-------------------------------|-------------------------------|
| Maternal age (years old) | 27.9 ± 7.3 | 31.2 ± 7.1 | 25.1 ± 5.6 |
| First-trimester GA assessment (weeks) | 12.8 ± 0.6 | 12.7 ± 5.8** | 12.4 ± 0.6 |
| Second-trimester GA assessment (weeks) | 21.7 ± 1.3 | 20.9 ± 0.8 | 21.3 ± 1.1 |
| Third-trimester GA assessment (weeks) | 29.5 ± 1.0 | 28.9 ± 0.6 | 28.9 ± 0.6 |
| Ethnic origin | | | |
| Mixed | 54 (100) | 8 (100) | 10 (100) |
| Primigravida | 18 (33.3) | 0 (0) | 4 (40) |
| Comorbidities | | | |
| Diabetes mellitus | 0 (0) | 0 (0) | 1 (10) |
| Chronic hypertension | 1 (1.85)* | 3 (37.5) | 1 (10) |
| Obesity | 4 (7.4) | 2 (25) | 0 (0) |
| Chronic renal failure | 0 (0) | 0 (0) | 1 (10) |
| Anemia | 1 (1.85) | 1 (12.5) | 0 (0) |
| Hypothyroidism | 0 (0) | 0 (0) | 4 (40) |
| Low maternal weight | 4 (7.4) | 1 (12.5) | 1 (10) |
| Smoker | | | |
| Yes | 9 (16.6) | 2 (25) | 3 (30) |
| No | 45 (83.3)* | 6 (75) | 7 (70) |
| Personal history of PE | 2 (3.7)* | 3 (37.5) | 2 (20) |
| Family history of PE | 7 (12.9)* | 3 (37.5) | 4 (40) |
| BMI (kg/m²) | 24.9 ± 4.1 | 27.5 ± 5.8 | 23.8 ± 3.2 |

Abbreviations: APS, antiphospholipid syndrome; ASA, acetylsalicylic acid; BMI, body mass index; GA, gestational age; PE, preeclampsia; SLE, systemic erythematous lupus.

Data are presented as mean ± standard deviation or as n (%). *Indicates statistically significant differences between aspirin versus no aspirin groups. **Indicates statistically significant differences between groups aspirin before 14 weeks and after 14 weeks.
was 0.96 (95%CI: 0.19–0.98), which was also statistically significant. To achieve decrease and normalization of the mean UtA-PI at the 1st trimester compared with the third trimester, it was found that PR was 0.67 (CI 95% 0.38–1.16), although this difference was not statistically significant. In the ASA before the 14th week group, 37.5% of the patients had improvement in the mean UtA-PI at the 3rd trimester. The NNT was 22. In addition, it was found that women who did not take ASA had a PR of 1.62 (95%CI: 0.87–3.01), continuing with the abnormal mean UtA-PI at the 3rd trimester, although this difference was not statistically significant; and women who took ASA after 14 weeks had a PR of 1.14 (95%CI: 0.46–2.78), continuing with the mean UtA-PI > 95th percentile at the 3rd trimester, although this difference was not statistically significant either (Table 2).

### Table 2

| Characteristics | Prevalence ratio | 95%CI |
|-----------------|-----------------|-------|
| When the mean UtA PI was abnormal at the first trimester and then it was normal at the second and/or third trimesters | 0.95 | 0.31–1.89 |
| When the mean UtA PI was abnormal at the first trimester and then it was normal at the second trimester | 0.92 | 0.21–0.99 |
| When the mean UtA PI was abnormal at the first and second trimesters and then it was normal at the third trimester | 0.96 | 0.19–0.98 |
| When the mean UtA PI was abnormal at the first trimester and then it was normal at the third trimester | 0.67 | 0.38–1.16 |
| No ASA intake or started it after 14 weeks of gestation | 1.62 | 0.87–3.01 |

Abbreviations: ASA, acetylsalicylic acid; CI, confidence interval; UtA PI, uterine arteries pulsatility index.

### Discussion

Worldwide, PE complicates 2 to 3% of all pregnancies; but in developing countries, the incidence increases up to 8%, being the main cause of maternal death in Colombia in 2017.1,3,5–7 Although the pathophysiology of PE has not been completely understood, there is evidence that impaired trophoblastic invasion of the spiral arteries is one of the underlying causes. Abnormal UtA Doppler at the 1st trimester is a reflection of increased resistance to flow and a nonspecific biomarker of prediction of early PE.25 The onset of ASA at the 1st trimester of pregnancy has shown to have an effect on the reduction of the incidence of preterm PE in high-risk patients39 and of the incidence for small for gestational age (SGA) and fetal growth restriction (FGR).20 However, there are very few studies that evaluate the performance of the mean UtA-PI in patients taking ASA.

In the present study, there were statistically significant changes in the assessment of the mean UtA-PI of participants taking ASA compared with those who did not take it. This is reflected in the participants with abnormal mean UtA-PI at the 1st trimester who had 0.92 times more probability of normalizing the mean UtA-PI at the 2nd trimester compared with those who did not take ASA as a factor protector. Additionally, regarding improvement of the mean UtA-PI at the 3rd trimester, it was found that women who took ASA had 0.67 times more probability of decreasing the mean UtA-PI at the 3rd trimester, although this difference was not statistically significant. In this case, for every 22 participants treated with ASA, an improvement of the mean UtA-PI was obtained in 1 woman between the 1st and 3rd trimesters.
Furthermore, it is important to take into account what happened with the uterine arteries of the participants who did not take ASA or did so after 14 weeks, who were, respectively, 1.62 and 1.14 times more likely of continuing with the mean UtA PI > 95th percentile at the 3rd trimester, as a risk factor, although this difference was not statistically significant.

The results of the present study differ with those of the study by Scazzocchio et al.,9 a randomized trial that included 155 patients with abnormal 1st trimester UtA Doppler, in which 75 patients received placebo and 80 received ASA. They evaluated whether low doses of ASA administered from the 1st trimester improved trophoblastic invasion assessed by UtA Doppler at 28 weeks, and no significant effect was found. However, these authors compared the mean UtA-PI between the two groups to determine if there were significant differences and not the normalization of Doppler, as in our study.9 On the other hand, in the study of Haapamo et al.33 that included 37 patients who had undergone 2 techniques of assisted reproduction (in-vitro fertilization and intracytoplasmic sperm injection), it was observed that the PI of the right and left UtAs at 18 weeks was lower in the ASA group compared with the placebo group when ASA was started before pregnancy ($p < 0.05$), but normalization of the UtA-PI was not reported. Therefore, the results of the aforementioned studies cannot be compared with those of our study because they did not evaluate the improvement in UtA-PI and it may be worth considering that if this parameter changes, it also changes the normal limits in patients who take ASA from the 1st trimester.

In the present study, the outcome of presentation of diseases related to placentation such as hypertensive disorders of pregnancy or fetal growth disturbances were not evaluated, so it cannot be said that the normalization of the mean UtA-PI in these participants was associated with a decrease in the onset of these disorders. There could be a selection bias since the data in this study are extracts from the main study whose objective was to evaluate PE screening and correspond to a specific population. Furthermore, random error due to the small sample size of this study is acknowledged.

More studies with a greater number of participants would be needed to determine if the change of the mean of UtA-PI as the pregnancy progresses is clinically relevant in the assessment of patients with risk of PE or of intrauterine growth restriction, and if it is justified to change the reference values of the 95th percentile, discriminating whether the participants were taking ASA or not.

**Conclusion**

The intake of ASA in patients with abnormal UtA-PI at the 1st trimester was associated with a normalization statistically significant of this parameter at the 2nd or 3rd trimesters. More studies are needed to determine if these results could modify the usual clinical obstetrical care.

---

**References**

1. Lisonkova S, Sabr Y, Mayer C, Young C, Skoll A, Joseph KS. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol. 2014;124(04):771–781. Doi: 10.1097/AOG.0000000000000472
2. Ahumada JS, Barrera AM, Canosa D, et al. Risk factors for preterm birth in Bogotá, D.C., Colombia. Rev Fac Med (Caracas). 2020;68(04):556–563. Doi: 10.15446/revfacmed.v68n4.297902 Spanish
3. Uriel M, Romero XC. Reality of preeclampsia in Colombian pregnant women. J Gynecol. 2016;1(01):000105
4. Romero XC, Gutiérrez AM, Rojas NA, et al. Incidence of hypertensive disorders in pregnancy and clinical-demographic characteristics in pregnant women in three institutions in Bogotá, D.C., Colombia. Investig Segur Soc Salud.. 2018;20(02):21–30
5. Guzmán-Yara YN, Parra-Amaya E, Javela-Rugeles JD. Expectant management in non-severe pre-eclampsia, obstetric and perinatal outcomes in a high complexity hospital in Neiva (Colombia). Colomb J Obstet Gynecol. 2018;69(03):160–168. Doi: 10.18597/rcog.3075
6. Buitrago-Gutiérrez G, Castro-Sanguino A, Cifuentes-Borrero R, Osorio-Guzman MP, Arevalo-Rodriguez I, Gomez-Sánchez PI. [Clinical practice guidelines for approaching pregnancy-associated hypertensive complications]. Colomb J Obstet Gynecol. 2013;64(03):289–326 Spanish
7. Amaya-Guío J, Díaz-Cruz LA, Cardona-Ospina A, Rodríguez-Mercán DM, Osorio-Sánchez D, Barrera-Barinas A. [Clinical practice guidelines for the prevention and early detection of pregnancy disorders]. Colomb J Obstet Gynecol. 2013;64(03):245–288 Spanish
8. Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin J Am Soc Nephrol. 2016;11(06):1102–1113. Doi: 10.2215/CJN.12081115
9. Scazzocchio E, Oros D, Diaz D, Ramirez JC, Ricart M, Meler E, et al. Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11–14 weeks: a randomized controlled study. Ultrasonob Obstet Gynecol. 2017;49(04):435–441. Doi: 10.1002/ugo.17351
10. Liu S, Shimizu I, Suehara N, Nakayama M, Aono T. Uterine artery Doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstet Gynecol. 1995;85(S Pt 1):760–765. Doi: 10.1016/0029-7844(95)00020-r
11. Papageorghiou AT, Yu CK, Bindra R, Pandis G, Nicolaides KH. Fetal Medicine Foundation Second Trimester Screening Group. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasonob Obstet Gynecol. 2001;18(05):441–449. Doi: 10.1046/j.0960-7692.2001.00572.x
12. Poon LC, Karagiannis G, Leal A, Romero XC, Nicolaides KH. Hypertensive disorders in pregnancy: screening by uterine artery
Doppler imaging and blood pressure at 11-13 weeks. Ultrasound Obstet Gynecol. 2009;34(05):497–502. Doi: 10.1002/uog.7439
13 O’Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M, et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017;49(06):756–760. Doi: 10.1002/uog.17455
14 O’Gorman N, Wright D, Syngelaki A, Akolekhar R, Wright A, Poon LC, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016;214(01):103.e1–103.e12. Doi: 10.1016/j.ajog.2015.08.034
15 Rolnik DL, Wright D, Poon LCY, Syngelaki A, O’Gorman N, de Paco Matallana C, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50 (04):492–495. Doi: 10.1002/uog.18816
16 Tsiaakis A, Saiid Y, Wright A, Wright D, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks’ gestation. Am J Obstet Gynecol. 2016; 215(01):87.e1–87.e17. Doi: 10.1016/j.ajog.2016.02.016
17 Sharma N, Srinivasan S, Srinivasan KJ, Nadhamuni K. Role of aspirin in high pulsatility index of uterine artery: a consort study. J Obstet Gynaecol India. 2018;68(05):382–388. Doi: 10.1007/ s13224-017-1058-4
18 Askie LM, Duley L, Henderson-Smart DJ, Stewart LAPARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369 (9575):1791–1798. Doi: 10.1016/S0140-6736(07)60712-0
19 Rolnik DL, Wright D, Poon LC, O’Gorman, Syngelaki, de Paco Matallana, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(07): 613–622. Doi: 10.1056/NEJMoa1704559
20 Tomni G, Araujo Júnior E, Bonasoni MP. Physiopathology. In: Nardozza L, Araujo Júnior E, Rizzo G, Deter R, editors. Fetal growth restriction: current evidence and clinical practice. Cham: Springer; 2019:41–64
21 Bujold E, Morency AM, Roberge S, Lacasse Y, Forest JC, Gigüere Y. Acetylsalicylic acid for the prevention of preeclampsia and intrauterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2009;31(09):818–826. Doi: 10.1016/S1701-2163 (16)34300-6
22 Bhide A, Acharya G, Bilardo CM, Brezinka C, Cafić D, Hernandez-Andrade E, et al. ISUOG practice guidelines: use of Doppler ultrasonography in obstetrics. Ultrasound Obstet Gynecol. 2013;41(02):233–239. Doi: 10.1002/uog.12371
23 Sotiriadis A, Hernandez-Andrade E, da Silva Costa F, Ghi T, Blanc P, Khalil A, et al; ISUOG CSC Pre-eclampsia Task Force. ISUOG Practice Guidelines: role of ultrasound in screening for and follow-up of pre-eclampsia. Ultrasound Obstet Gynecol. 2019; 53(01):7–22. Doi: 10.1002/uog.20105
24 Plasencia W, Maiz N, Poon L, Yu C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2008;32(02):138–146. Doi: 10.1002/uog.5402
25 Martin AM, Bindra R, Curcio P, Cicero S, Nicolaides KH. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation. Ultrasound Obstet Gynecol. 2001;18(06):583–586. Doi: 10.1046/j.0960-7692.2001.00594.x
26 Gómez O, Figueras F, Fernández S, Bennasar M, Martínez JM, Puerto B, et al. Reference ranges for uterine artery mean pulsatility index at 11-41 weeks of gestation. Ultrasound Obstet Gynecol. 2008;32(02):128–132. Doi: 10.1002/uog.5315
27 Coutinho LM, Scazufca M, Menezes PR. Methods for estimating prevalence ratios in cross-sectional studies. Rev Saude Publica. 2008;42(06):982–988. Doi: 10.1590/0034-89102008000600003
28 Deddens JA, Petersen MR. Approaches for estimating prevalence ratios. Occup Environ Med. 2008;65(07):481–, 501–506. Doi: 10.1136/oem.2007.034777
29 Schiaffino A, Rodríguez M, Pasarín MI, Regidor E, Borrell C, Fernández E. [Odds ratio or prevalence ratio? Their use in cross-sectional studies]. Gac Sanit. 2003;17(01):70–74. Doi: 10.1016/s0213-9111(03)71694-x
30 Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? Occup Environ Med. 1998;55(04):272–277. Doi: 10.1136/oem.55.4.272
31 World Medical Association. WMA Declaration of Helsinki: ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, Jun 1964 [Internet] 2018 [cited 2020 Dec 15]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
32 Ministerio de Salud. Resolución No. 8430, de 4 de octubre de 1993 [Internet]. Por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud 1993 [cited 2020 Dec 15]. Available from: https://www.urosario.edu.co/Escuela-Medicina/Investigacion/Documentos-de-interes-/Files/resolucion_008430_1993.pdf
33 Haapsamo M, Martikainen H, Räsänen J. Low-dose aspirin reduces uteroplacental vascular impedance in early and mid gestation in IVF and ICSI patients: a randomized, placebo-controlled double-blind study. Ultrasound Obstet Gynecol. 2008;32(05):687–693. Doi: 10.1002/uog.6215